Get the Stockscreener App
117.84
0.45%
0.53
Pre-market:
123.99
6.15
+5.22%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Chicago Capital LLC - MarketBeat
Molluscum Contagiosum Market Expected to rise, 2034 | Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barchart
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
BlackRock, Inc. Reduces Stake in Ligand Pharmaceuticals Inc. - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Hantz Financial Services Inc. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Looking Back On Ligand Pharmaceuticals (NASDAQ:LGND) - Seeking Alpha
Court Place Advisors LLC Sells 7,700 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Investors in Ligand Pharmaceuticals (NASDAQ:LGND) have seen decent returns of 53% over the past year - Simply Wall St
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Burney Co. Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
JPMorgan Chase & Co. Lowers Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Lowered by JPMorgan Chase & Co. - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
LGND (Ligand Pharmaceuticals) Debt-to-EBITDA : 0.54 (As of Sep. 2024) - GuruFocus.com
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Don't Ignore The Insider Selling In Ligand Pharmaceuticals - Simply Wall St
Principal Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Is Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Recent Price Movement Underpinned By Its Weak Fundamentals? - Simply Wall St
Jane Street Group LLC Sells 7,790 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Jane Street Group LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Octavio Espinoza Executes Sell Order: Offloads $244K In Ligand Pharmaceuticals Stock - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year - Yahoo Finance
MML Investors Services LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Octavio Espinoza Sells 2,104 Shares - MarketBeat
Ligand Pharmaceuticals CFO Espinoza sells $244,850 in stock By Investing.com - Investing.com Canada
Benchmark maintains Buy on Ligand Pharma stock citing consistent financial performance - Investing.com Canada
Geode Capital Management LLC Acquires 22,495 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Holdings Raised by Geode Capital Management LLC - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Receives “Buy” Rating from Benchmark - Defense World
Benchmark Reaffirms Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND) - MarketBeat
Franklin Resources Inc. Has $9.79 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Barclays PLC Has $4.35 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Stifel Financial Corp Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Holdings Lifted by HighTower Advisors LLC - Defense World
Wellington Management Group LLP Decreases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
What is Zacks Small Cap's Forecast for LGND FY2025 Earnings? - MarketBeat
Zacks Small Cap Issues Optimistic Estimate for LGND Earnings - Defense World
Zacks Small Cap Has Strong Estimate for LGND FY2026 Earnings - MarketBeat
Fmr LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals: A Strong Growth Trajectory with Impressive Returns and Strategic Advancements - mediahousepress
LGND: 2025 View Calls for 17% Topline Growth - Zacks Small Cap Research
Ligand Pharmaceuticals' SWOT analysis: diversified royalty model drives stock growth - Investing.com Australia
Barclays Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $160.00 - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):